| EDAP Appoints Dr. John C. Rewcastle as International Medical Director
LYON, France, June 28 /PRNewswire-FirstCall/ -- EDAP TMS S.A. , the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, announces the appointment of Dr. John C. Rewcastle as International Medical Director. Dr Rewcastle's duties will include significant involvement in the company's accelerating US clinical trial as well as general education and research roles associated with the clinical program in North America. "The goal of all prostate cancer therapies is to effectively treat the disease but not impact the patient's quality of life," said Dr. Rewcastle. "I believe that HIFU has the ability to meet this goal for the majority of patients diagnosed with localized prostate cancer. Further, the Ablatherm-HIFU device is ideally suited for the North American market, and I foresee rapid adoption following FDA approval." Dr.
Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and ...
NEW YORK, June 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. today announced that 4 posters were presented at the 11th International Myeloma Workshop demonstrating the clinical activity of KRX-0401 (perifosine) in patients with advanced multiple myeloma and Waldenstrom's macroglobulinemia. Perifosine is currently being evaluated in 3 ongoing, multi-center clinical studies for patients with relapsed or relapsed/refractory multiple myeloma, including in combination with dexamethasone, in combination with Velcade(R) (bortezomib) and in combination with Revlimid(R) (lenalidomide) plus dexamethasone. Perifosine is also being evaluated in an ongoing phase II single agent study in patients with relapsed and/or refractory Waldenstrom's macroglobulinemia. Data from each of these ongoing studies was presented during the conference and demonstrates perifosine's activity, both as a single agent and as part of a combination, in patients with multiple myeloma and Waldenstrom's macroglobulinemia.
Edward Cancer Center Treats Lung Cancer With Novel Adaptive
Naperville, IL - Clinicians at Edward Hospital here are using Trilogy technology from Varian Medical Systems to offer some cancer patients a novel treatment that adapts to changes in the tumor so that more healthy tissue can be preserved. This is particularly promising in the treatment of lung cancer, when breathing is already compromised and the doctor must spare as much healthy lung tissue as possible. In one case, doctors discovered a very large, fast growing tumor in a 69-year-old former smoker who had developed a persistent cough and wheezing. Tests revealed that she had small cell lung cancer, an aggressive form of the disease. "We needed to use radiation right away to shrink the tumor quickly, because it was collapsing her lung and making it difficult for her to breathe," said Vasudha Lingareddy, MD, medical director of the Edward Cancer Center Department of Radiation Oncology.
|
